CGON Net Interest Income from 2010 to 2024

CGON Stock   33.90  0.05  0.15%   
CG Oncology, Net Interest Income yearly trend continues to be very stable with very little volatility. Net Interest Income is likely to grow to about 7.2 M this year. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. View All Fundamentals
 
Net Interest Income  
First Reported
2010-12-31
Previous Quarter
6.9 M
Current Value
7.2 M
Quarterly Volatility
2.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CG Oncology, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CG Oncology,'s main balance sheet or income statement drivers, such as Net Interest Income of 7.2 M, Depreciation And Amortization of 15.4 K or Interest Expense of 7.2 M, as well as many indicators such as Price To Sales Ratio of 750, Dividend Yield of 0.0 or PTB Ratio of 0.83. CGON financial statements analysis is a perfect complement when working with CG Oncology, Valuation or Volatility modules.
  
Check out the analysis of CG Oncology, Correlation against competitors.

Latest CG Oncology,'s Net Interest Income Growth Pattern

Below is the plot of the Net Interest Income of CG Oncology, Common over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. CG Oncology,'s Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CG Oncology,'s overall financial position and show how it may be relating to other accounts over time.
Net Interest Income10 Years Trend
Slightly volatile
   Net Interest Income   
       Timeline  

CGON Net Interest Income Regression Statistics

Arithmetic Mean582,680
Coefficient Of Variation453.06
Mean Deviation1,731,712
Median(451,000)
Standard Deviation2,639,862
Sample Variance7T
Range7.7M
R-Value0.61
Mean Square Error4.7T
R-Squared0.37
Significance0.02
Slope358,148
Total Sum of Squares97.6T

CGON Net Interest Income History

20247.2 M
20236.9 M
2022 -1000.0

About CG Oncology, Financial Statements

CG Oncology, investors utilize fundamental indicators, such as Net Interest Income, to predict how CGON Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Interest Income6.9 M7.2 M

Pair Trading with CG Oncology,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to CG Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology, Common to buy it.
The correlation of CG Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether CG Oncology, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CG Oncology,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cg Oncology, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cg Oncology, Common Stock:
Check out the analysis of CG Oncology, Correlation against competitors.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.036
Quarterly Revenue Growth
1.727
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.